Y. Laurian

发表

Risk of inhibitors in haemophilia and the type of factor replacement

J. Goudemand, Y. Laurian, T. Calvez, 2006, Current opinion in hematology.

Incidence of Factor VIII Inhibitor Development in Severe Hemophilia A Patients Treated only with One Brand of Highly Purified Plasma-Derived Concentrate

C. Rothschild, M. Bertrand, C. Négrier, 1995, Thrombosis and Haemostasis.

French Previously Untreated Patients with Severe Hemophilia A after Exposure to Recombinant Factor VIII : Incidence of Inhibitor and Evaluation of Immune Tolerance

P. Moreau, C. Rothschild, J. Goudemand, 1998, Thrombosis and Haemostasis.

A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group.

P. Mannucci, Y. Laurian, C. Kasper, 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

Incidence of Factor IX Inhibitor Development in Severe Haemophilia B Patients Treated with only one Brand of High Purity Plasma Derived Factor IX Concentrate

C. Rothschild, V. Gay, C. Guérois, 1999, Thrombosis and Haemostasis.

Randomized double‐blind, placebo‐controlled trial of twice‐daily zidovudine in asymptomatic haemophiliacs infected with the human immunodeficiency virus type 1

A. Gringeri, P. Mannucci, Y. Laurian, 1994 .

Lack of detection of human immunodeficiency virus type 1 DNA by polymerase chain reaction in the plasma and lymphocytes of seronegative exposed hemophiliacs

Y. Laurian, D. Henrard, W. F. Mehaffey, 1993, Transfusion.

Assessment by gene amplification and serological markers of transmission of HIV-1 from hemophiliacs to their sexual partners and secondarily to their children.

I. Hewlett, J. Epstein, Y. Laurian, 1990, Journal of acquired immune deficiency syndromes.

Future perspective for the treatment of hemophilia A

Y. Laurian, 2005, Journal of thrombosis and haemostasis : JTH.

Use of Recombinant Factor VIIa in 3 Patients with Inherited Type I Glanzmann’s Thrombasthenia Undergoing Invasive Procedures

P. Nurden, C. Négrier, R. d'Oiron, 2000, Thrombosis and Haemostasis.

SEROLOGICAL MARKERS IN EARLY STAGES OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN HAEMOPHILIACS

Y. Laurian, J. Allain, D. Paul, 1986, The Lancet.

HIV infection in sexual partners of HIV-seropositive patients with hemophilia.

Y. Laurian, J. Peynet, F. Verroust, 1989, New England Journal of Medicine.

AIDS in subjects with hemophilia.

Y. Laurian, F. Verroust, M. Archambeaud, 1990, The New England journal of medicine.

The French haemophilia cohort: rationale and organization of a long-term national pharmacosurveillance system.

D. Costagliola, C. Rothschild, Y. Laurian, 2001 .

The French haemophilia cohort: rationale and organization of a long‐term national pharmacosurveillance system

D. Costagliola, C. Rothschild, Y. Laurian, 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.

T. Lambert, C. Rothschild, A. Borel‐Derlon, 2006, Blood.

Treatment of Bleeding in Patients with Platelet Disorders: Is There a Place for Recombinant Factor VIIa?

Y. Laurian, 2002, Pathophysiology of Haemostasis and Thrombosis.

structural proteins: clinical significance Monitoring of specific antibodies to human immunodeficiency virus

M. Einstein, Y. Laurian, J. Allain, 2011 .

Splenectomy is safe and effective in human immunodeficiency virus-related immune thrombocytopenia.

É. Oksenhendler, S. Chevret, P. Bierling, 1993, Blood.

Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents.

R. Zotz, G. Di Minno, J. Knudsen, 2006, Seminars in hematology.

Thrombosis of Haemostasis Treatment of Bleeding in Patients with Platelet Disorders : Is There a Place for Recombinant Factor VIIa ?

Y. Laurian, 2002 .

ANTIBODIES TO HEPATITIS C VIRUS IN HAEMOPHILIA

P. Maisonneuve, C. Guérois, Y. Laurian, 1989, The Lancet.

The prevalence of antibody to HTLV‐I/II in United States plasma donors and in United States and French hemophiliacs

D. Brettler, G. Leckie, Y. Laurian, 1990, Transfusion.

Comparison of Anti‐Human and Anti‐Porcine Factor VIII Inhibitor Levels in 63 Patients with Severe Haemophilia A

M. Torchet, M. Bertrand, B. Boneu, 1993, Vox sanguinis.

Author and Subject Index

Owen P. Smith, Christine A. Lee, Y. Laurian, 2002, Pathophysiology of Haemostasis and Thrombosis.

Monitoring of specific antibodies to human immunodeficiency virus structural proteins: clinical significance

M. Einstein, Y. Laurian, J. Allain, 1991 .

Monitoring of specific antibodies to human immunodeficiency virus structural proteins: clinical significance.

M. Einstein, Y. Laurian, J. Allain, 1991, Blood.

inhibitors in previously untreated patients with severe hemophilia A Influence of the type of factor VIII concentrate on the incidence of factor VIII

T. Lambert, C. Rothschild, A. Borel‐Derlon, 2013 .

Management of haemophilic arthropathy

N. Stieltjes, Y. Laurian, Y. Carrillon, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

Synovectomy of the elbow in young hemophilic patients.

Y. Laurian, M. Larrieu, M. Ebelin, 1987, The Journal of bone and joint surgery. American volume.

Compliance with Early Long-Term Prophylaxis Guidelines for Severe Hemophilia A.

K. Baumstarck, P. Moreau, T. Lambert, 2021, The Journal of pediatrics.

Patello-femoral syndrome in hemophiliac knee.

Y. Laurian, J. Allain, M. Larrieu, 1978, Acta orthopaedica Belgica.

Transmission of human parvovirus B19 by plasma derived factor VIII concentrates.

Y. Laurian, A. Parquet, G. Tchernia, 1994, Nouvelle revue francaise d'hematologie.

Clinical Trials of Recombinant Factor VIII

P. Mannucci, C. Kessler, H. Kingdon, 1991 .

Factor VIII gene inversions in severe hemophilia A: results of an international consortium study.

F E Preston, P G Mori, S S Sommer, 1995, Blood.

Orthopaedics and Haemophilia

M. Blombäck, G. Lüchters, F. Mandelli, 1981 .

Viral contamination of blood products

B. Colvin, Y. Laurian, J. Lusher, 1994, The Lancet.

Induction of Tolerance Using Porcine Factor VIII

C. Hay, Y. Laurian, 1996, Vox sanguinis.

Induction of immune tolerance in patients with hemophilia A and inhibitors treated with porcine VIIIC by home therapy.

C. Hay, Y. Laurian, F. Preston, 1990, Blood.

inhibitors treated with porcine VIIIC by home therapy Induction of immune tolerance in patients with hemophilia A and

C. Hay, Y. Laurian, F. Preston, 2011 .

Absence of anamnestic response after transfusion of washed red blood cells in haemophilia A patients with antibody to factor VIII.

Y. Laurian, M. Larrieu, J. Girma, 2009, Scandinavian journal of haematology.

Protective effect of prophylaxis on inhibitor development in children with haemophilia A: more convincing studies are required

Y. Laurian, T. Calvez, 2006, British journal of haematology.

Inhibitor incidence with recombinant vs. plasma‐derived FVIII in previously untreated patients with severe hemophilia A: homogeneous results from four published observational studies

J. Goudemand, Y. Laurian, T. Calvez, 2008, Journal of thrombosis and haemostasis : JTH.

Comparison of Anti-Human and Anti-Porcine Factor Vlll Inhibitor

M. Torchet, M. Bertrand, B. Boneu, 2009 .

[Efficacy in viral inactivation of the concentrates of factor VIII and IX by the solvent/detergent procedure. Evaluation in patients with hemophilia].

C. Guérois, Y. Laurian, M. Vicariot, 1991, Presse medicale.

Detection of 95 novel mutations in coagulation factor VIII gene F8 responsible for hemophilia A: results from a single institution

T. Lambert, B. Guillet, A. Rafowicz, 2006, Human mutation.

Evidence for persistent hepatitis C virus (HCV) infection in hemophiliacs.

A. Rafowicz, S. Desai, Y. Laurian, 1991, The Journal of clinical investigation.

Long-term evaluation of HIV antigen and antibodies to p24 and gp41 in patients with hemophilia. Potential clinical importance.

M. Leuther, Y. Laurian, C. Gazengel, 1987, The New England journal of medicine.

High frequency of herpes zoster in young hemophiliacs.

Y. Laurian, D. Lemay, F. Verroust, 1987, The New England journal of medicine.

Development of a PCR-based method coupled with a microplate colorimetric assay for the detection of Porcine Parvovirus and application to diagnosis in piglet tissues and human plasma.

Y. Laurian, P. Blanchard, A. Jestin, 1998, Molecular and cellular probes.

Haemophilia B Due to a De Novo Insertion of a Human-Specific Alu Subfamily Member within the Coding Region of the Factor IX Gene

M. Vidaud, D. Vidaud, M. Goossens, 1993, European journal of human genetics : EJHG.

Detection of a molecular defect in 40 of 44 patients with haemophilia B by PCR and denaturing gradient gel electrophoresis

M. Vidaud, D. Vidaud, J. Lavergne, 1993, British journal of haematology.

Immune thrombocytopenia gammaglobulin, and positivity to the human T-lymphotropic virus type III.

Y. Laurian, A. Ellrodt, P. Alvin, 1986, Annals of internal medicine.

Predictive value of viral load and other markers for progression to clinical AIDS after CD4+ cell count falls below 200/μL

C. Rouzioux, M. Chavance, L. Meyer, 1998 .

[Aregenerative anemia and erythrocytes hemighosts: a case report].

Y. Laurian, S. Sauvion, L. De Pontual, 2011, Annales de biologie clinique.

All Exposed Hemophiliacs Have Markers of HCV

Y. Laurian, J. Allain, S. Delaney, 1992, Vox sanguinis.

Antibody to hepatitis C (anti C 100-3) in French hemophiliacs.

C. Guérois, Y. Laurian, A. Couroucé, 1991, Nouvelle revue francaise d'hematologie.

Relevance of anti-nef antibody detection as an early serologic marker of human immunodeficiency virus infection.

L. Montagnier, E. Bahraoui, Y. Laurian, 1990, Blood.

Progression to AIDS in French haemophiliacs: association with HLA-B35.

D. Costagliola, Y. Laurian, Y. Sultan, 1993, AIDS.

Immunologic and virologic status of multitransfused patients: role of type and origin of blood products. By the AIDS-Hemophilia French Study Group.

A. Goudeau, C. Guérois, Y. Laurian, 1985, Blood.

Non‐A, Non‐B Hepatitis in Hemophilic Patients with Inhibitor Treated with Activated Prothrombin Complex Concentrates: Lack of Correlation with an Antigen Possibly Related to Non‐A, Non‐B Hepatitis

Y. Laurian, C. Gazengel, J. Hellings, 1984, Vox sanguinis.

[Anti-HCV and recipients: situation in hemophiliacs in 1991].

C. Guérois, Y. Laurian, A. Parquet‐Gernez, 1992, Revue francaise de transfusion et d'hemobiologie : bulletin de la Societe nationale de transfusion sanguine.

Is rituximab effective in acquired von Willebrand syndrome?

Y. Laurian, R. Dhôte, O. Fain, 2009, British journal of haematology.

A randomized, double‐blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors

Shapiro, Kasper, Y. Laurian, 1998 .

Erythema dyschromicum perstans following human immunodeficiency virus seroconversion in a child with hemophilia B.

Y. Laurian, P. Venencie, D. Lemay, 1988, Archives of dermatology.

[Peripheral and bone marrow plasmacytosis in dengue fever: report of a case].

J. Stirnemann, Y. Laurian, A. Morin, 2009, La Revue de medecine interne.

Randomized double-blind, placebo-controlled trial of twice-daily zidovudine in asymptomatic haemophiliacs infected with the human immunodeficiency virus type 1. European-Australian Haemophilia Collaborative Study Group.

P. Mannucci, A. Gringeri, Y. Laurian, 1994, British journal of haematology.